News

The UN Friends of Vision group meeting coincided with International Women's Day and the UN Commission on the Status of Women

The retinal implant delivers continuous neurotrophic support, potentially halting disease progression and paving the way for future treatments in neurodegenerative retinal disorders.

Hashad is a retinal specialist with over 25 years of leadership experience in global research and development.

A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia were included along with 45 healthy individuals.

A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden

Urcosimod, formerly known as OK-101, showed clear statistical significance in multiple endpoints in a recently completed Phase 2 trial

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary antibody biopolymer conjugate (ABC) platform.

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported

Additionally, the prognosis of macular oedema may help clinicians evaluate renal function, investigators reported

Clinicians react to the US approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) for macular telangiectasia type 2

A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia were included along with 45 healthy individuals.

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal disease

Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune cells of the eye responsible for the inflammatory response.

4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

Key parameters captured by the module include disc area, cup area, cup volume, minimal cup depth, maximum cup depth, cup/disc area ratio, rim absence angle, and disc-damage likelihood scale.

This database could enhance the workflow of eye care professionals with its in-depth reference data for retinal layer thickness and optic nerve head metrics.

Ronne steps into leadership role as the ASO marks a historic milestone on International Women’s Day

Researchers set out to determine the age groups for which a polygenic risk score would most effectively predict glaucomatous risk and help inform cost-effective methods for disease detection.

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).

ENCELTO is the first and only FDA-approved treatment for MacTel.

The novel nitric oxide-donating bimatoprost eye drop is designed to lower IOP in patients with open-angle glaucoma or ocular hypertension

In a keynote speech, Warren Hoburg and Tyson J. Brunstetter, OD, PhD, will discuss in-orbit imaging and spaceflight-associated neuro-ocular syndrome

Visual acuity with both approaches was comparable and the device was efficacious and safe.

Retina Resource was developed by retina specialists for retina specialists.

NCX 470 0.1% achieved an intraocular pressure of less than or equal to 18 mmHg compared to latanoprost 0.005% in the trial.

Neurologist warns about recurrent optic neuritis attacks.

The Australia-based organisation is partnering with the UN Friends of Vision group for an event on 11 March